全文获取类型
收费全文 | 4255篇 |
免费 | 319篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 19篇 |
儿科学 | 145篇 |
妇产科学 | 206篇 |
基础医学 | 590篇 |
口腔科学 | 118篇 |
临床医学 | 497篇 |
内科学 | 688篇 |
皮肤病学 | 30篇 |
神经病学 | 334篇 |
特种医学 | 183篇 |
外科学 | 554篇 |
综合类 | 98篇 |
一般理论 | 1篇 |
预防医学 | 418篇 |
眼科学 | 113篇 |
药学 | 263篇 |
中国医学 | 10篇 |
肿瘤学 | 320篇 |
出版年
2021年 | 55篇 |
2020年 | 38篇 |
2019年 | 55篇 |
2018年 | 60篇 |
2016年 | 52篇 |
2015年 | 47篇 |
2014年 | 71篇 |
2013年 | 141篇 |
2012年 | 174篇 |
2011年 | 162篇 |
2010年 | 113篇 |
2009年 | 98篇 |
2008年 | 158篇 |
2007年 | 176篇 |
2006年 | 162篇 |
2005年 | 141篇 |
2004年 | 152篇 |
2003年 | 143篇 |
2002年 | 122篇 |
2001年 | 121篇 |
2000年 | 122篇 |
1999年 | 99篇 |
1998年 | 66篇 |
1997年 | 57篇 |
1996年 | 52篇 |
1995年 | 53篇 |
1994年 | 59篇 |
1993年 | 36篇 |
1992年 | 125篇 |
1991年 | 111篇 |
1990年 | 121篇 |
1989年 | 101篇 |
1988年 | 102篇 |
1987年 | 113篇 |
1986年 | 70篇 |
1985年 | 107篇 |
1984年 | 76篇 |
1983年 | 72篇 |
1982年 | 43篇 |
1981年 | 48篇 |
1980年 | 51篇 |
1979年 | 87篇 |
1978年 | 55篇 |
1977年 | 38篇 |
1975年 | 32篇 |
1974年 | 31篇 |
1972年 | 38篇 |
1970年 | 45篇 |
1968年 | 31篇 |
1967年 | 36篇 |
排序方式: 共有4587条查询结果,搜索用时 15 毫秒
61.
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. 总被引:11,自引:0,他引:11
Shazli N Malik Lillian L Siu Eric K Rowinsky Linda deGraffenried Lisa A Hammond Jinee Rizzo Sarah Bacus Michael G Brattain Jeffrey I Kreisberg Manuel Hidalgo 《Clinical cancer research》2003,9(7):2478-2486
BACKGROUND: OSI-774 is an inhibitor of the epidermal growth factor receptor tyrosine kinase (EGFR-TK) currently in clinical development. In preclinical models, the antitumor activity of OSI-774 was directly related to its ability to inhibit the EGFR-TK. On the basis of these data, we hypothesized that inhibition of the EGFR-TK will be required for this agent to be effective in the clinic. This study evaluated the pharmacodynamic effects of OSI-774 in normal skin tissues collected from patients treated with the agent in a Phase I study. METHODS: Patients with advanced cancer who were treated in a Phase I study of OSI-774 underwent a biopsy of normal skin epidermis at baseline and after the last dose of drug in the first course of treatment. The expression and activation of the EGFR, downstream signaling extracytoplasmatic-regulated kinase (Erk), and cell cycle regulator p27 were determined in paraffin-embedded skin tissues using an immunohistochemical method (IHC). The IHC data were analyzed using both a semiquantitative scoring system and an automatic absorbance quantitative IHC method. The number of cells with nuclear staining of p27 per 500 cells was determined. Plasma samples were collected to quantitate OSI-774 plasma concentrations. RESULTS: A total of 56 skin specimens was collected from 28 patients treated with OSI-774 at doses ranging from 25 to 200 mg/day. There was a significant decrease in phospho-EGFR (Tyr 1173) expression as determined semiquantitatively with OSI-774 treatment [2.75 +/- 0.51 (mean +/- SD) pretreatment versus 2.36 +/- 0.76 after treatment, pair comparison P = 0.01]. The quantitative ratio [(phopho-EGFR/EGFR) x 100] of phospho-EGFR (Tyr1173) decreased from 64.16 +/- 36.58 pretreatment to 48.87 +/- 35.37 post-treatment (pair comparison, P = 0.02). No significant differences were observed in phospho-Erk (Thr202/Tyr204) expression. The mean number of cells with nuclear staining for p27 increased from 185 +/- 101 (mean +/- SD) pretreatment to 253 +/- 111 post-treatment (pair comparison P = 0.02). A total of 12 (42.8%), 7 (25%), and 14 (50%) patients had >25% variation in the ratio of phospho-EGFR (Tyr1173), phospho-Erk (Thr202/Tyr204), and p27 expression, respectively. Only changes in p27 expression were related to the administered dose of OSI-774. CONCLUSIONS: OSI-774 exerted pharmacodynamic effects in skin tissues of 30-50% of patients treated with the agent. Up-regulation of p27, which is a downstream effect of EGFR inhibition, was dose related. Although there was a significant decrement in phospho-EGFR (Tyr1173), it was not related to the administered dose of OSI-774. On the basis of these findings and the relatively simple and reliable method to measure p27 expression, this biomarker appears to be the most promising and is being evaluated in Phase II studies as a predictor of clinical outcome. 相似文献
62.
Val158Met Polymorphism in catechol-O-methyltransferase gene associated with risk factors for breast cancer. 总被引:5,自引:0,他引:5
Chi-Chen Hong Henry J Thompson Cheng Jiang Geoffrey L Hammond David Tritchler Martin Yaffe Norman F Boyd 《Cancer epidemiology, biomarkers & prevention》2003,12(9):838-847
Extensive mammographic density is heritable, strongly associated with increased breast cancer risk, and is influenced by sex hormone exposure. In a cross-sectional study of 181 pre- and 171 postmenopausal women without breast cancer, we examined the relationship of a functional polymorphism in catechol-O-methyltransferase (COMT; VAL-->MET) to mammographic density and other risk factors for breast cancer. We hypothesized that individuals who inherited the low-activity form of COMT (COMT*2 allele) would have higher levels of breast density, presumably because of reduced inactivation/detoxification of catecholestrogens. Subjects were recruited across five categories of breast density. Risk factor information, anthropometric measures, and blood samples were obtained; sex hormone and growth factor levels were measured, and COMT genotypes determined. Mammograms were digitized and measured using a computer-assisted method. After adjustment for age and ethnicity, among pre- but not postmenopausal subjects, each low-activity COMT*2 allele was associated with lower levels of percentage breast density. The statistical significance of this association was lost after further adjustment for serum growth factors [growth hormone, insulin-like growth factor-1 (IGF-1), and insulin-like growth factor binding protein-3 (IGFBP-3)], hormones [follicle-stimulating hormone (FSH) and progesterone], and body size (body mass index and waist:hip ratio). The low-activity COMT*2 allele was also associated, after adjustment for age and ethnicity in premenopausal women, with lower serum levels of IGF-1, higher levels of FSH and progesterone, and with a larger waist:hip ratio, body mass index, and subscapular skinfold. After adjustment for body size, the associations of genotype with IGFBP-3 and FSH were no longer significant. These findings indicate that COMT genotype is associated with several risk factors for breast cancer and suggest that the low-activity COMT*2 allele is associated with a reduced risk of breast cancer among premenopausal women. 相似文献
63.
64.
Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the childhood cancer survivor study. 总被引:1,自引:0,他引:1
Joanna L Perkins Yan Liu Pauline A Mitby Joseph P Neglia Sue Hammond Marilyn Stovall Anna T Meadows Ray Hutchinson Zoann E Dreyer Leslie L Robison Ann C Mertens 《Journal of clinical oncology》2005,23(16):3733-3741
PURPOSE: Nonmelanoma skin cancer (NMSC) has become the most common type of cancer in many populations throughout the world. Ultraviolet and ionizing radiation are known risk factors. Because NMSCs are rarely lethal and most cancer registries do not routinely report data regarding these cancers, they have received little attention in studies evaluating long-term effects of cancer therapy. This article reports on the occurrence of secondary NMSC as a long-term effect of cancer therapy in survivors of childhood cancer. PATIENTS AND METHODS: The Childhood Cancer Survivor Study (CCSS) is a cohort study of 5-year survivors of childhood and adolescent cancer from 25 participating institutions in North America. NMSC patients were defined by a history of basal cell or squamous cell carcinoma of the skin after primary malignancy treatment. Demographic and treatment data were collected and analyzed. RESULTS: Among the 13,132 eligible CCSS participants, 213 have reported NMSC; 99 patients (46%) have had multiple occurrences. Median age of occurrence was 31 years (range, 7 to 46 years). Location of NMSC included head and neck (43%), back (24%), chest (22%), abdomen and pelvis (5%), extremity (3%), and unknown (4%). Ninety percent of patients had previously received radiation therapy (RT); 90% of tumors occurred within the RT field. RT was associated with a 6.3-fold increase in risk (95% CI, 3.5- to 11.3-fold). CONCLUSION: Long-term survivors of childhood and adolescent cancer who were treated with RT are at highest risk for developing NMSC. Educational efforts need to be directed to this population to facilitate early diagnosis of NMSC and reduction in sun exposure. 相似文献
65.
BACKGROUND: Long-term outcome is important in managing traumatic brain injury (TBI), an epidemic in the United States. Many injury severity variables have been shown to predict major morbidity and mortality. Less is known about their relationship with specific long-term outcomes. METHODS: Glasgow Coma Scale, Revised Trauma Score, Injury Severity Score, and Trauma and Injury Severity Score, along with other demographic and premorbid values, were obtained for 378 consecutive patients hospitalized after TBI at a Level I trauma center between September 1997 and May 1998. Of this cohort, 120 patients were contacted for 1-year follow-up assessment with the Disability Rating Scale, Community Integration Questionnaire, and employment data. RESULTS: Univariate analyses showed these to be significant single predictors of 1-year outcome. Multivariate analyses revealed that the Revised Trauma Score and Glasgow Coma Scale had significant additive value in predicting injury variables Disability Rating Scale scores when combined with other demographic and premorbid variables studied. Predictive models of 1-year outcome were developed. CONCLUSION: Injury severity variables are significant single outcome predictors and, in combination with premorbid and demographic variables, help predict long-term disability and community integration for individuals hospitalized with TBI. 相似文献
66.
Marielle E. Yohe Christine M. Heske Elizabeth Stewart Peter C. Adamson Nabil Ahmed Cristina R. Antonescu Eleanor Chen Natalie Collins Alan Ehrlich Rene L. Galindo Berkley E. Gryder Heidi Hahn Sharon Hammond Mark E. Hatley Douglas S. Hawkins Madeline N. Hayes Andrea Hayes‐Jordan Lee J. Helman Simone Hettmer Myron S. Ignatius Charles Keller Javed Khan David G. Kirsch Corinne M. Linardic Philip J. Lupo Rossella Rota Jack F. Shern Janet Shipley Sivasish Sindiri Stephen J. Tapscott Christopher R. Vakoc Leonard H. Wexler David M. Langenau 《Pediatric blood & cancer》2019,66(10)
Overall survival rates for pediatric patients with high‐risk or relapsed rhabdomyosarcoma (RMS) have not improved significantly since the 1980s. Recent studies have identified a number of targetable vulnerabilities in RMS, but these discoveries have infrequently translated into clinical trials. We propose streamlining the process by which agents are selected for clinical evaluation in RMS. We believe that strong consideration should be given to the development of combination therapies that add biologically targeted agents to conventional cytotoxic drugs. One example of this type of combination is the addition of the WEE1 inhibitor AZD1775 to the conventional cytotoxic chemotherapeutics, vincristine and irinotecan. 相似文献
67.
Jean-Pierre Valentin Chris Pollard Pierre Lainée Tim Hammond 《British journal of pharmacology》2010,159(1):25-33
Non-clinical QT-related assays aligned to the pharmaceutical drug discovery and development phases are used in several ways. During the early discovery phases, assays are used for hazard identification and wherever possible for hazard elimination. The data generated enable us to: (i) establish structure–activity relationships and thereby; (ii) influence the medicinal chemistry design and provide tools for effective decision making; and provide structure–activity data for in silico predictive databases; (iii) solve problems earlier; (iv) provide reassurance for compound or project to progress; and (v) refine strategies as scientific and technical knowledge grows. For compounds progressing into pre-clinical development, the ‘core battery’ QT-related data enable an integrated risk assessment to: (i) fulfil regulatory requirements; (ii) assess the safety and risk–benefit for compound progression to man; (iii) contribute to defining the starting dose during the phase I clinical trials; (iv) influence the design of the phase I clinical trials; (v) identify clinically relevant safety biomarkers; and (vi) contribute to the patient risk management plan. Once a compound progresses into clinical development, QT-related data can be applied in the context of risk management and risk mitigation. The data from ‘follow-up’ studies can be used to: (i) support regulatory approval; (ii) investigate discrepancies that may have emerged within and/or between non-clinical and clinical data; (iii) understand the mechanism of an undesirable pharmacodynamic effect; (iv) provide reassurance for progression into multiple dosing in humans and/or large-scale clinical trials; and (v) assess drug–drug interactions. Based on emerging data, the integrated risk assessment is then reviewed in this article, and the benefit–risk for compound progression was re-assessed. Project examples are provided to illustrate the impact of non-clinical data to support compound progression throughout the drug discovery and development phases, and regulatory approval.This article is part of a themed section on QT safety. To view this issue visit http://www3.interscience.wiley.com/journal/121548564/issueyear?year=2010 相似文献
68.
Billy R. Hammond John Buch Lisa M. Renzi-Hammond Jenny M. Bosten Derek Nankivil 《Journal of vision》2023,23(1)
We assessed the effect of a contact lens that filters short-wavelength (SW) visible light on color appearance. These effects were modeled and measured by direct comparison to a clear contact lens. Sixty-one subjects were enrolled, and 58 completed as cohort; 31 were 18 to 39 years old (mean ± SD, 29.6 ± 5.6), 27 were 40 to 65 years old (50.1 ± 8.1). A double-masked contralateral design was used; participants randomly wore a SW-filtering contact lens on one eye and a clear control lens on the other eye. Subjects then mixed three primaries (including a short-wave primary, strongly within the absorbance of the test lens) until a perceived perfect neutral white was achieved with each eye. Color appearance was quantified using chromaticity coordinates measured with a spectral radiometer within a custom-built tricolorimeter. Color vision in natural scenes was simulated using hyperspectral images and cone fundamentals based on a standard observer. Overall, the chromaticity coordinates of matches that were set using the SW-filtering contact lens (n = 58; x = 0.345, y = 0.325, u′ = 0.222, v′ = 0.470) and clear contact lens (n = 58; x = 0.344, y = 0.325, u′ = 0.223, v′ = 0.471) were not significantly different, regardless of age group. Simulations indicated that, for natural scenes, the SW-filtering contact lens that was evaluated changes L/(L+M) and S/(L+M) chromatic contrast by no more than −1.4% to +1.1% and −36.9% to +5.0%, respectively. Tricolorimetry was used to measure color appearance in subjects wearing a SW-filtering lens in one eye and a clear lens in the other, and the results indicate that imparting a subtle tint to a contact lens, as in the SW-filtering lens that was evaluated, does not alter color appearance for younger or older subjects. A model of color vision predicted little effect of the lens on chromatic contrast for natural scenes. 相似文献
69.
Bacterial resistance to antiseptics and disinfectants 总被引:15,自引:0,他引:15
70.